Completed PHASE2 INTERVENTIONAL 1-arm NCT01132820

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Sponsor: NRG Oncology

Conditions Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Endometrial Clear Cell Adenocarcinoma Endometrial Serous Adenocarcinoma Recurrent Uterine Corpus Carcinoma

Interventions Cediranib Maleate Laboratory Biomarker Analysis

Updated 8 times since 2017 Last updated: Aug 6, 2019 Started: Jun 30, 2010 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01132820, this PHASE2 trial focuses on Endometrial Adenocarcinoma and Endometrial Adenosquamous Carcinoma and remains completed. Sponsored by NRG Oncology, it has been updated 8 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NRG Oncology
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Baltimore, United States , Bellingham, United States , Bremerton, United States , Burbank, United States , Camden, United States , Chanute, United States , Charlotte, United States , Chicago, United States , Cincinnati, United States and 51 more locations